Richard J Rebello
Richard J Rebello
Geverifieerd e-mailadres voor manchester.ac.uk
Titel
Geciteerd door
Geciteerd door
Jaar
Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer
MJ Watt, AK Clark, LA Selth, VR Haynes, N Lister, R Rebello, LH Porter, ...
Science translational medicine 11 (478), 2019
892019
Therapeutic approaches targeting MYC-driven prostate cancer
RJ Rebello, RB Pearson, RD Hannan, L Furic
Genes 8 (2), 71, 2017
542017
AMP-activated protein kinase selectively inhibited by the type II inhibitor SBI-0206965
TA Dite, CG Langendorf, A Hoque, S Galic, RJ Rebello, AJ Ovens, ...
Journal of Biological Chemistry 293 (23), 8874-8885, 2018
522018
The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer
RJ Rebello, E Kusnadi, DP Cameron, HB Pearson, A Lesmana, JR Devlin, ...
Clinical Cancer Research 22 (22), 5539-5552, 2016
472016
Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity
I Takizawa, MG Lawrence, P Balanathan, R Rebello, HB Pearson, E Garg, ...
Oncotarget 6 (2), 604, 2015
422015
Patient-derived models of abiraterone-and enzalutamide-resistant prostate cancer reveal sensitivity to ribosome-directed therapy
MG Lawrence, D Obinata, S Sandhu, LA Selth, SQ Wong, LH Porter, ...
European urology 74 (5), 562-572, 2018
412018
From sphingosine kinase to dihydroceramide desaturase: a structure–activity relationship (SAR) study of the enzyme inhibitory and anticancer activity of 4-((4-(4-chlorophenyl …
L Aurelio, CV Scullino, MR Pitman, A Sexton, V Oliver, L Davies, ...
Journal of medicinal chemistry 59 (3), 965-984, 2016
372016
Identification of Pik3ca mutation as a genetic driver of prostate cancer that cooperates with Pten loss to accelerate progression and castration-resistant growth
HB Pearson, J Li, VS Meniel, CM Fennell, P Waring, KG Montgomery, ...
Cancer Discovery 8 (6), 764-779, 2018
352018
Proteomic profiling of human prostate cancer-associated fibroblasts (CAF) reveals LOXL2-dependent regulation of the tumor microenvironment
EV Nguyen, BA Pereira, MG Lawrence, X Ma, RJ Rebello, H Chan, ...
Molecular & Cellular Proteomics 18 (7), 1410-1427, 2019
322019
The influence of BRCA2 mutation on localized prostate cancer
RA Taylor, M Fraser, RJ Rebello, PC Boutros, DG Murphy, RG Bristow, ...
Nature Reviews Urology 16 (5), 281-290, 2019
292019
PIM activity in tumours: A key node of therapy resistance
RJ Rebello, AV Huglo, L Furic
Advances in biological regulation 67, 163-169, 2018
202018
mTOR-mediated podocyte hypertrophy regulates glomerular integrity in mice and humans
VG Puelles, JW Van Der Wolde, N Wanner, MW Scheppach, ...
JCI insight 4 (18), 2019
192019
Translational offsetting as a mode of estrogen receptor α‐dependent regulation of gene expression
J Lorent, EP Kusnadi, V van Hoef, RJ Rebello, M Leibovitch, J Ristau, ...
The EMBO journal 38 (23), e101323, 2019
102019
Identification of Pik3ca mutation as a genetic driver of prostate cancer that cooperates with Pten loss to accelerate progression and castration-resistant growth. Cancer Discov …
HB Pearson, J Li, VS Meniel, CM Fennell, P Waring, KG Montgomery, ...
CD-17-0867.[Abstract][CrossRef][Google Scholar], 0
10
Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Sci Transl Med. 2019; 11
MJ Watt, AK Clark, LA Selth, VR Haynes, N Lister, R Rebello
5
TP53 and prognosis in mCRPC Survival: Biology or Coincidence?
RJ Rebello, C Oing, S Gillessen, RG Bristow
Clinical Cancer Research 25 (6), 1699-1701, 2019
22019
PO-230 Cysteine-rich secretory protein 3 regulates progression from in situ to invasive prostate cancer
M Volpert, J Hu, R Rebello, M O’Bryan, L Furic
ESMO Open 3 (Suppl 2), A317-A317, 2018
22018
Intermediate risk prostate cancer: disease heterogeneity linked to measurable biological features
RJ Rebello, RG Bristow
Clinical Oncology 32 (5), 298-302, 2020
12020
Abstract PO-032: Mechanistic studies of hypoxia as a driver of genomic instability in prostate cancer
J Ashton, R Rebello, S Lyons, RG Bristow
Clinical Cancer Research 27 (8 Supplement), PO-032-PO-032, 2021
2021
Abstract PO-035: Understanding the role of hypoxia and PTEN loss in driving prostate cancer progression
A Suvac, R Rebello, S Lyons, RG Bristow
Clinical Cancer Research 27 (8 Supplement), PO-035-PO-035, 2021
2021
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20